For which patients with active Still's disease is canakinumab (Ilaris) indicated?

Canakinumab (Ilaris) is indicated for active Still's disease, including adult-onset Still's disease and systemic juvenile idiopathic arthritis, in patients aged 2 years and older who responded inadequately to previous therapy with NSAIDs and systemic corticosteroids, as monotherapy or with methotrexate.